Health utilities in Alzheimer’s disease and implications for cost-effectiveness analysis

被引：0
|
作者：
Peter J. Neumann
机构：
[1] Harvard School of Public Health,Department of Health Policy and Management and Center for Risk Analysis
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Memantine; Rivastigmine; Health Utility; Clinical Dementia Rate; Health Utility Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The National Institute for Health and Clinical Excellence (NICE) provisional decision against memantine and other medications for Alzheimer’s disease (AD) has generated much discussion. In its decision, NICE expressed concern about the data source used for the utility scores in the industry submission of the memantine model. NICE therefore turned to an alternative data source. However, in doing so, it made the key assumption that moderate-to-severe AD patients living in the community were independent. Furthermore, the NICE data source also had its limitations.
引用
收藏
页码：537 / 541
页数：4
相关论文
共 50 条
  • [1] Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis
    Neumann, PJ
    [J]. PHARMACOECONOMICS, 2005, 23 (06) : 537 - 541
  • [2] An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease
    Busschbach, JJV
    Brouwer, WBF
    van der Donk, A
    Passchier, J
    Rutten, FFH
    [J]. PHARMACOECONOMICS, 1998, 13 (01) : 21 - 34
  • [3] An Outline For a Cost-Effectiveness Analysis of a Drug For Patients With Alzheimer’s Disease
    Jan J.V. Busschbach
    Werner B.F. Brouwer
    Adrianus van der Donk
    Jan Passchier
    Frans F.H. Rutten
    [J]. PharmacoEconomics, 1998, 13 : 21 - 34
  • [4] Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease
    Oremus, Mark
    Tarride, Jean-Eric
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 275 - 277
  • [5] COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN
    Mesterton, J.
    By, A.
    Sandelin, R.
    Jonsson, L.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A369 - A369
  • [6] The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK
    Zala, Darshan
    Chan, Dennis
    McCrone, Paul
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (02) : 307 - 315
  • [7] Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan
    Fuh, Jong-Ling
    Wang, Shuu-Jiun
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (01) : 73 - 78
  • [8] Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil
    da Silva, Luciana R.
    Vianna, Cid M. M.
    Mosegui, Gabriela B. G.
    Peregrino, Antonio A. F.
    Marinho, Valeska
    Laks, Jerson
    [J]. BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (03) : 218 - 224
  • [9] Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer's Disease
    Lin, Chung-Hsien
    Fann, Jean Ching-Yuan
    Chen, Sam Li-Sheng
    Chen, Hsiu-Hsi
    Yang, Kuen-Cheh
    [J]. CURRENT ALZHEIMER RESEARCH, 2019, 16 (06) : 495 - 504
  • [10] Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease
    Yang, Kuen-Cheh
    Chen, Hsiu-Hsi
    [J]. CURRENT ALZHEIMER RESEARCH, 2016, 13 (07) : 809 - 816
12345